OUR SCIENCE
Therapeutics
Ex vivo gene silencing enabled
cell therapies
Laverock is developing programmable cell therapies in two core areas – regenerative medicine and oncology. Regenerative medicine applications are focused on Type 1 diabetes, where we are generating engineered hypoimmune pancreatic islet cells, targeting product profiles with improved safety, efficacy and accessibility.
Oncology programs are seeking to address the considerable challenge in development of cell therapies that can resist and remain active in the immunosuppressive tumour microenvironment, associated with solid-tumours. In this context we can programmably enable cellular phenotypes with improved efficacy without negative safety implications.
Our Pipeline
Engineered, iPSC-derived pancreatic islet cells with programmable hypoimmune status.
Oncology: Programmed T-cells for solid tumoursEngineered, autologous T-cells for solid tumour indications: enhanced potency and resistance to exhaustion.
Programmed macrophages for solid tumoursEngineered, iPSC-derived macrophages with enhanced functionality for solid tumour indications: anti-tumour efficacy, resisting TAM formation
In-vivo therapeutics
Our programmable, tunable, stable and specific gene silencing platform is widely applicable to addressing a range of disease areas. We are generating proof of concept data and actively seeking partners to exemplify its differentiation from existing in-vivo RNAi modalities, and ability for a ‘once-and-done’ RNAi approach.
Find out about the fundamental science and discovery platform that underpins our therapeutics pipeline.
